Rae A P, Beattie J M, Lawrie T D, Hutton I
Br J Clin Pharmacol. 1985 Mar;19(3):343-52. doi: 10.1111/j.1365-2125.1985.tb02653.x.
A randomised double-blind parallel group study was performed to compare the clinical efficacy of bepridil, a new calcium slow channel blocker, with that of propranolol and placebo in patients with chronic stable angina of effort. Efficacy was assessed objectively by dynamic exercise testing using an upright bicycle ergometer and subjectively by patient documentation of anginal frequency and nitrate consumption. The administration of bepridil resulted in a significant improvement in physical work capacity expressed as calculated maximal oxygen uptake (Vo2 max) and exercise time. This was associated with subjective improvement in terms of reduced anginal frequency. Despite baseline differences in exercise performance and anginal frequency between the three treatment groups, the beneficial effects of bepridil were statistically significant when compared to propranolol. Although minor electrocardiographic changes were noted, no adverse effects were evident when bepridil was prescribed in doses of up to 400 mg/day over a 10 week period.
进行了一项随机双盲平行组研究，以比较新型钙慢通道阻滞剂苄普地尔与普萘洛尔及安慰剂对慢性稳定劳力性心绞痛患者的临床疗效。通过使用直立式自行车测力计进行动态运动试验客观评估疗效，并通过患者记录心绞痛发作频率和硝酸酯类药物消耗量主观评估疗效。苄普地尔治疗使以计算的最大摄氧量（Vo2 max）和运动时间表示的体力工作能力有显著改善。这与心绞痛发作频率降低的主观改善相关。尽管三个治疗组在运动表现和心绞痛发作频率方面存在基线差异，但与普萘洛尔相比，苄普地尔的有益效果具有统计学意义。尽管注意到有轻微的心电图变化，但在为期10周的时间内，以每日最高400 mg的剂量服用苄普地尔未发现明显不良反应。
